TheraP
Prostate — In Follow-up
TheraP
Lutetium-177 PSMA radionuclide therapy (Lu-PSMA) is a new treatment for advanced prostate cancer. Lu-PSMA is a radioactive molecule that specifically attaches to cells with high amounts of PSMA on the surface of the cells. This allows the radioactivity to be delivered mainly to the prostate cancer cells wherever they have spread, while sparing most normal tissues. Previous small studies of Lu-PSMA showed promising activity in patients with advanced prostate cancer.
This randomised study will compare Lu-PSMA with a type of chemotherapy called cabazitaxel, which is the standard treatment for advanced prostate cancer when other treatments have stopped working. Half the participants will receive Lu-PSMA and half will receive cabazitaxel. This study will provide further information about the risks and benefits of Lu-PSMA compared with cabazitaxel in people with prostate cancer. We plan to enrol 200 participants in the study in Australia.
Further TheraP Information
This randomised study will compare Lu-PSMA with a type of chemotherapy called cabazitaxel, which is the standard treatment for advanced prostate cancer when other treatments have stopped working. Half the participants will receive Lu-PSMA and half will receive cabazitaxel. This study will provide further information about the risks and benefits of Lu-PSMA compared with cabazitaxel in people with prostate cancer. We plan to enrol 200 participants in the study in Australia.
Further TheraP Information
If you think this trial might be right for you, please ask your doctor.
Trial Title
A randomised phase II trial of 177Lu-PSMA617 theranostic versus cabazitaxel in progressive metastatic castration resistant prostate cancer
Cancer Type
Prostate
Trial Status
In Follow-up
Protocol Number
ANZUP 1603
Trial Email
Co-ordinating centre
Study Chair
Professor Michael Hofman
Patient Population
Men with mCRPC suitable for cabazitaxel chemotherapy.
Recruitment Target
200 participants
Acknowledgements
TheraP is a partnership between ANZUP Cancer Trials Group and the Prostate Cancer Foundation of Australia (PCFA) with support from the Australian Nuclear Science and Technology Organisation (ANSTO), Endocyte, It’s a Bloke Thing, Movember and CAN4CANCER
Detailed Information
Further Information
Latest Publication
Participating Centres
NSW
St Vincent's Hospital - Sydney
Royal North Shore Hospital - Northern Sydney Local Health District
Liverpool Hospital - South Western Sydney Local Health District
Calvary Mater Newcastle
VIC
Austin Hospital
Monash Cancer Center - Moorabbin
Peter MacCallum Cancer Centre
QLD
Royal Brisbane & Women's Hospital
SA
Royal Adelaide Hospital - Central Adelaide Local Health Network Inc.
WA
Fiona Stanley Hospital
Sir Charles Gairdner Hospital